Background/Aims: To investigate the renal phenotype under conditions of an activated morphology in wild-type, ET-1 transgenic (ET+/+), endothelial nitric oxide synthase knockout (eNOS-/-) and ET+/+eNOS-/-mice. Methods: We assessed blood pressure, parameters of renal morphology, plasma cystatin C, urinary protein excretion, expression of genes using metabolomics. Results: eNOS-/-and ET+/+eNOS-/-mice developed hypertension. Osteopontin, albumin and protein excretion were increased in eNOS-/-and restored in and glomerulosclerosis. Genes involved in tissue remodeling (serpine1, TIMP1, Col1a1, CCL2) were up-regulated in eNOS-/-, but not in ET+/+eNOS-/-mice. Plasma levels of free carnitine and acylcarnitines, amino acids, diacyl phosphatidylcholines, lysophosphatidylcholines and hexoses were descreased in eNOS-/-and were in the normal range in ET+/+eNOS-/-mice. Conclusion: eNOS-/-mice developed renal dysfunction, which was partially rescued by ET-1 overexpression in eNOS-/-mice. The metabolomics results suggest that ET-1 overexpression on top of eNOS knockout is associated with a functional recovery of mitochondria (rescue of monounsaturated fatty acids levels).
Introduction
Endothelin-1 (ET-1) and nitric oxide (NO) closely interact in a manner of a local network, i.e. ET-1 stimulates NO production, NO in turn inhibits ET-1 expression proportionally in different cell-types [1] . An in vivo example of interaction between ET-1 and NO production was demonstrated in transgenic mice overexpressing ET-1 (ET+/+), which have a normal blood pressure. The vasoconstrictory effects of ET-1 were antagonized by an increased production of NO, the endothelial counterpart of ET-1 in animals overexpressing .
An excessive renal production of ET-1 is often observed in patients with chronic kidney disease (CKD) of diabetic and non-diabetic origin [3] . In contrast, in CKD the overall NO availability is decreased, in part due to endothelial dysfunction [4] . To date, the only known agents to block the activity of ET-1, which have been approved for clinical use, are ET receptor antagonists [5] , although they have not so far been validated for a therapeutic use in CKD due to adverse effects such as water and salt retention [3, 6] .
We have previously generated crossbred animals of ET transgenic mice (ET+/+) and endothelial nitric oxide synthase knockout (eNOS-/-) mice to investigate the role of ET-1 overproduction in endothelial function and blood pressure in the conditions of NO /-and ET+/+eNOS-/-mice developed high blood pressure in contrast to wild-type (WT) and ET+/+ mice, which remained normotensive [8] . Interestingly, left ventricular catheterization showed that only eNOS-/-mice, but not ET+/+eNOS-/-developed diastolic dysfunction [8] . The aim of the present work was to investigate renal phenotypic consequences and mechanisms of ET/eNOS interaction using crossbred ET+/+eNOS-/-mice.
Materials and Methods

Mouse model
Human ET-1 transgenic mice (line 856) [9] and eNOS-/-mice [10] were generated as described previously. Only homozygous mice were used for breeding. We ensured the steadiness of the genotype over the generations. Crossbred mice were created by breeding female eNOS-/-mice with male ET+/+. Study groups were composed as follows: WT, ET+/+, eNOS-/-, and ET+/+eNOS-/-mice. The number of animals The protocol was approved by the Committee on the Ethics of Animal Experiments of the city of Berlin, Germany.
Blood pressure months).
Histological studies
to the total area of the picture was analyzed using the program ImageJ (shareware by National Institutes acid-Schiff positive area within the glomerulus by a semi-quantitative score system using a score of 1-4 by two investigators who were blinded to the study groups. Scores 1, 2, 3, and 4 represented mesangial matrix Plasma and urinary analyses Urinary concentrations of albumin, H-FABP, and osteopontin were determined in urine samples collected in a six hours time period in metabolic cages. ELISA assays were conducted to determine the levels of albumin (CellTrend GmbH kit. no. 50200, Luckenwalde, Germany), H-FABP (Hycult Biotech, kit no. HK403, protocols provided by the suppliers of the assays. Optical density of the samples was measured at 450 nm creatinine, albumin, and protein were quantitatively determined in the samples using a Cobas Integra 400 Systems Inc. (Minneapolis, MN, USA) according to manufacturer's guidelines with readout performed with Western blotting . separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Amersham   TM   Hybond   TM ECL, GE Healthcare, Milwaukee, USA) in transfer buffer (184 mM Glycin, 24 mM Tris, 20% methanol) at 110 V for 2.5 hours. Membranes were blocked in 5% non-fat milk TBS-T for Aldrich, Steinheim, Germany) were used.
Germany) and checked for integrity on a Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). For Carlsbad, CA, USA) for 15 minutes at room temperature and then reverse-transcribed with the use of ImProm well microtiter plates. cDNA samples (20 ng) were run in triplicates in reaction volumes of 20 μl (384-well microtiter plates) under standard thermocycler conditions. TaqMan probe sets were generated by using Primer3Plus ( was calculated using the ddCt term (Applied Biosystems, User Bulletin No. 2) related to endogenous controls the following NCBI GenBank accession numbers (Table 1) .
IDQ
TM p150 kit injection analysis) [12, 13] . The assay includes free carnitine, 40 acylcarnitines (Cx:y), 14 amino acids (13 proteinogenic + ornithine), hexoses (sum of hexoses -about 90-95 % glucose), 92 glycerophospholipids The abbreviations Cx:y are used to describe the total number of carbons and double bonds of all chains, respectively [13] . Mass spectrometric (MS) analyses were done on a API 4000 system (AB Sciex Deutschland GmbH, Darmstadt, Germany) equipped with a 1200 Series HPLC (Agilent Technologies Deutschland GmbH, Böblingen, Germany) and a HTC PAL auto sampler (CTC Analytics, Zwingen, Switzerland) controlled by the of metabolite concentrations as well as quality assessment was performed with the MetIQ™ software, which is an integral part of the AbsoluteIDQ™ kit (both from Biocrates Life Sciences AG, Innsbruck, Austria).
The AbsoluteIDQ TM p150 kit has been proven to be in conformance with FDA-Guidline "Guidance for Industry -Bioanalytical Method Validation" (May 2001) [14] , which implies proof of reproducibility within a given error range. The metabolite panel covered by targeted metabolomics approach has been succesfully used to evaluate mechanistic background of phenotypes observed in human [15] 
Statistical analysis
All data are expressed as means ± SEM. Statistical analyses were performed using GraphPad Prism 5 software (La Jolla, CA, USA). For comparison of two parametrically distributed groups of data unpaired t-test with equal or unequal variance (Welch's correction) was applied. For nonparametrically distributed when P < 0.05.
Results
Systolic blood pressure P < 0.001 versus WT) P < 0.05 versus WT) compared to WT (111.9 ± 4.2 tendencies were revealed starting as early as 3 months of age (Table 2) . SBP in eNOS-/-Plasma cystatin C was elevated in both groups with eNOS genetic ablation (P < 0.05 versus WT), but not in ET+/+ mice (Fig. 1a) . In contrast, albuminuria and proteinuria were P < 0.01 versus WT) increased only in eNOS-/-compared to WT (15.0-control. Interestingly, in crossbred mice both albuminuria and proteinuria levels were observed to be diminished compared to eNOS-/-(P < 0.01 versus eNOS-/-). Urine biomarkers Urinary excretion of osteopontin was 3.4-fold increased in eNOS-/-mice versus WT (P < 0.01) and restored in crossbred mice versus eNOS-/-(P < 0.001, Fig. 2a ). Urinary excretion of heart muscle-type fatty acid binding protein (H-FABP, measured in ng/24h) was the genotypes (Fig. 2b) .
Kidney morphology
ET+/+eNOS-/-versus WT, whereas in the eNOS-/-group it was lower compared to all other groups (Table 3) . ET+/+, eNOS-/-and ET+/+eNOS-/-mice all developed glomerulosclerosis, as assessed by increased deposits of periodic acid Schiff (PAS) positive material within the groups.
The eNOS protein expression was increased in the ET+/+ group (P < 0.01 versus WT).
in Table 4 . Table 2 . Systolic Blood Pressure. Systolic blood pressure in 3 and 9 months old mice, mm Hg. Values are given as mean ± SEM. * P P P < 0.001 vs WT Fig. 1 . Plasma cystatin C levels (a), urinary albumin (b) and protein (c) daily excretion. Values are given as mean ± SEM. * P < 0.05, ** P < 0.01.
Fig. 2.
Values are given as mean ± SEM. * P P *** P < 0.001.
Podocyte-associated genes (podocalyxin-like protein 1, nephrin and integrin alpha 3 subunit) showed only minor regulation patterns (Fig. 3a-c) . In contrast, glomerular basement membrane (GBM) -associated genes were differently regulated. In ET+/+ and eNOS-/-mice a down-regulation of collagen IV gene expression was observed, whereas the gene encoding one of the laminin subunits (Lamc1) was up-regulated. Lamb2, a gene responsible for the synthesis of another laminin subunit, showed a trend (P = 0.056 versus WT) towards up-regulation in eNOS-/-mice. Crossbred animals showed only a minor regulation of GBM associated genes ( Fig. 3d-f ). Endothelial cells-associated genes CD34 and up-regulated in eNOS-/-animals compared to WT. Col1a1 gene showed a trend towards upin the ET+/+eNOS-/-mice. Interleukin 18 gene expression was up-regulated in ET+/+ mice versus all other groups (Fig. 4f) . The angiotensin I-converting enzyme 2 (ACE2) gene was down-regulated in eNOS-/-animals compared to all other groups (Fig. 4g) .
Plasma metabolites
Free carnitine and acyl carnitines (Fig. 5) , diacyl phosphatidylcholines (PCaa), exhibited a similar pattern, in which the metabolites in eNOS-/-or transgenic ET+/+ were lower in concentration, whereas these metabolites of crossbred (ET+/+eNOS-/-) animals were comparable in concentration to those found in WT animals. We did not observe changes in the activity of mitochondrial carnitine palmitoyl transferase I in any of the transgenic models, as depicted by a stable CPT-I ratio (calculated from octadecanoylcarnitine + hexadecanoylcarnitine/carnitine free (C18+C16)/C0). The oxidative degradation of even- Table 3 . mean ± SEM. * P P < 0.001 vs eNOS-/- numbered fatty acids in mitochondria (characterized by carnitine free/acetylcarnitine (C2/ C0) ratio) compared to the overall activity of ß-oxidation (measured by acetylcarnitine + propionylcarnitine/carnitine free (C2+C3)/C0) ratio) revealed the aforementioned pattern representative of each metabolite class. Desaturation of fatty acid chains in the PC(aa) or acyl carnitines abrogated the of their saturation level, revealed differences between WT, eNOS-/-and ET+/+ (Fig. 6d-f) . unit (c)), glomerular basement membrane-(collagen IV alpha 1 (d), laminin beta 2 (e), laminin gamma 1 (f)) and endothelial cells-associated genes (cluster of differentiation 34 (g) and cluster of differentiation 31 (h)) in whole kidney. Values are given as mean ± SEM. * P P P < 0.001.
Fig. 4.
plasminogen activator inhibitor-1 (a), tissue inhibitor of metalloproteinase 1 (TIMP-1) (b), collagen type I alpha 1 (c), connective tissue growth factor (d), chemokine (C-C motif) ligand 2 / monocyte chemoattractant protein-1 (e), interleukin 18 (f), angiotensin I-converting enzyme 2 (ACE2) (g). Values are given as mean ± SEM. * P P P < 0.001. , carnitine free/acetylcarnitine ratio (c), acetylcarnitine + propionylcarnitine/carnitine free ratio (d), dodecenoyl-L-carnitines C12 and C12:1 (e and f), tiglyl-L-carnitine (g), glutaconyl-L-carnitine (h). Values are given as mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001.
integrity. Increased urinary osteopontin excretion, (Fig. 2a) as well as renal expression of by ET-1 overexpression. In order to identify potential mechanisms leading to the restoration of the renal phenotype of eNOS-/-mice, we performed metabolomic analyses. These analyses indicated that ET-1 overexpression, in addition to an eNOS knockout is associated increase in antioxidative properties (normalization of monounsaturated fatty acids levels). Importantly, the phenotype of the ET-1 transgenic mice did not exhibit a measurable earlier reports indicating that kidney function in these animals starts to decrease in later stages (>12 months) [9] . Protein excretion was only seen in eNOS-/-mice [21] [22] [23] , but not in ET+/+ as reported earlier [9, 24, 25] . ET-1 overexpression on its own does not cause proteinuria, but in cases of underlying proteinuric renal diseases, such as pediatric nephrotic syndrome or diabetic renal disease, an activated ET-system enhances protein excretion [26] . Blood pressure was normal in ET-1+/+ mice, most likely due to an activated NO system generations of ET+/+eNOS-/-mice, the blood pressure was similar in eNOS-/-mice and ET+/+eNOS-/-mice [8, 24, 25] . The reasons why the blood pressure phenotype changes slightly over the years is still unknown.
One of the reasons for a leakage of plasma proteins into the urine might be a damaged basement membrane (GBM) and endothelial cells. Albumin-and proteinuria can be caused by disturbances of any GFB element [28] . In order to better understand the morphology of lined by a layer of interdigitating podocyte foot processes from the urinary-space side. Our seen in ET+/+eNOS-/-mice (Fig. 3) . The GBM itself is composed of extracellular matrix proteins assembled through an interweaving of type IV collagen with laminins, nidogen, and sulfated proteoglycans [29] . Any changes in the balance of extracellular matrix proteins within GBM may lead to an increased permeability. The eNOS-/-mice were characterized by pronounced changes in expression of WT), while Lamb2 showed a trend towards up-regulation (P = 0.056 versus WT). Similar, although less pronounced changes were revealed in ET+/+ mice, whereas in crossbreds GBM associated gene expression was similar to WT (Fig. 3d-f) . Mutations in genes encoding proteins, including integrins are known to act as osteopontin receptors [32] . Although their interaction in the context of renal dysfunction is not clear yet, it is known that osteopontin is osteopontin observed in eNOS-/- (Fig. 2) was consistent with an elevation of SBP (Table 1 ). In addition, we further analyzed renal expression of genes involved in tissue remodeling. In agreement with our assumption, increased urinary osteopontin excretion together with an up-regulation of osteopontin binding proteins Lamb2 and Lamc1 was accompanied by an upet al. previously reported that decreased NO levels in the kidney aggravated renal dysfunction, damage, hypertrophy, serum creatinine, blood urea nitrogen and urinary protein levels, accompanied by increases inhibitors of metalloproteinases [34] . Therefore, we suggest that the proteinuric phenotype in eNOS knockout mice is caused, at least partially, by an impaired GBM composition, which is improved in crossbred animals ( Fig. 3d-f) .
Our current data of an improvement of the functional consequences of a systemic eNOS /-, but not ET+/+eNOS-/-mice, developed cardiac dysfunction manifested in increased end diastolic pressure and time of left ventricular relaxation [8] . Cardioprotective properties of ET-1 overexpression on top of eNOS knockout were explained by reduction of cardiac oxidative et al. reported that in patients with CKD plasma ET-1 levels positively correlated with left ventricular hypertrophy [35] . The opposite effects of ET-1 overproduction in two different settings might be explained by a big heterogeneity within the patient cohort (concomitant chronic diseases, age, race etc. are the factors affecting organ function independently of ET-1 production) in the clinical trial, while our preclinical study was conducted in mice lines were shown to have much more pronounced renoprotective effect than nonselective ones.
excretion, SBP, or kidney morphology parameters in uremic rats with 5/6 nephrectomy [38] . The aforementioned effects of ET antagonists were investigated in CKD models such as 5/6 nephrectomy or diabetic nephropathy, however the pathophysological conditions induced in these models are different in comparison to the model used in our study, in which ET-1 overexpression was not combined with any other insult to the kidney. The kidney is very active in carnitine metabolism and releases the metabolites into the plasma and urine [39] . The metabolic pattern observed in the ET+/+eNOS-/-animals suggests a functional recovery of mitochondria. This effect is prominent for internal mitochondrial enzymes but not for the carnitine shuttle (CPT-I, EC 2.3.1.21) [40] . Furthermore, the same rescue effect is seen in oxidation of even-numbered fatty acids and overall activity oxidative damage in the renal cortex of hypertensive rats [42] . It results in an up-regulation of both antioxidant enzymes and eNOS [43] . Desaturation of fatty acid chains in the PC(aa) or carnitines abrogates the differences observed between WT, eNOS -/-and ET +/+, which is in agreement with the observation that saturated fatty acids (e.g. palmitic acids) activate and the underlying mechanisms were reported. In erythrocyte membrane lipid composition monounstaturated fatty acids (MUFA) are increased in non-diabetic patients with continuous ambulatory peritoneal dialysis [45] . In addition, MUFAs are increased in the plasma of activity [49] . Lysophosphatidylcholines (LPCs) are more sensitive to desaturation changes as they are composed of only one hydrocarbon chain instead of two present in the PCaas and PCaes. Peroxisomal metabolism of phosphatidylcholines is not affected in any of the models (neither single nor double mutants) included in our study as the levels of PC(ae)s were not affected [50] .
Similarly to concentrations of carnitines and lipids, the amino acid levels are normalized in ET+/+eNOS-/-animals. This is of interest as these metabolites are biomarkers of complex diseases like diabetes type 2 and CKD. Arginine is a known precursor of NO [51] and induces oxidative stress through a modulation of NOS activity. Short-term exposure causes an increase, and long term exposure a decrease of NOS activity in human endothelial cells [52] . tiglylcarnitine (C5:1) and glutaconylcarnitine (C5:1-DC) [53, 54] . The C5:1 is listed within a panel of biomarkers patented for the diagnosis of kidney disease [55] . Branched chain amino acids (BCAA, leucine, isoleucine and valine) constitute 40% of all amino acids from daily nutrition intake [56] . Changes in BCAA concentrations are risk biomarkers of diabetes type patients with CKD showed a decrease in BCAA which might as well be caused by malnutrition [60] . Metabolic exchange of BCAA between different tissues was observed to modulate BCAA metabolism in CKD [61] . BCAA can enter energy generation in tricarboxylic acid cycle (TCA) through the action of branched-chain alpha-keto acid dehydrogenase complex [62] . Branched translation via elF4E [64] . eNOS was shown to support both mitochondrial biogenesis and metabolic activity [65] . The restoration effects seen in ET+/+eNOS-/-animals in our study interpretation of the processes is summarized in Fig. 9 and is based on published and our own records.
with CKD and heart failure. We have demonstrated that the functional consequences of a lack by overexpression of ET-1. We suggest that this might be due to a functional recovery of properties (normalization of monounsaturated fatty acids levels). The current study is in agreement with a previous report showing that eNOS knockout mice develop diastolic dysfunction which could be restored by ET-1 overexpression in the heart. This study the regulation of cardiac proteins playing a role in oxidative stress, myocyte contractility, and energy metabolism [8] . Thus, besides the fact that blockade of both the ETA and ETB receptors may lead to water and salt retention [3, 5, 6] , our current data further challenges the idea to block the endothelin system in patients with endothelial dysfunction, as it is present in CKD due to diabetic nephropathy.
